ArticleThe British journal of surgery2026
Nationwide outcomes of fenestrated endovascular aneurysm repair.
Article in The British journal of surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundFenestrated endovascular aneurysm repair (FEVAR) is increasingly used in patients who are not eligible for standard endovascular aneurysm repair (EVAR) devices due to anatomical constraints, principally of the proximal aortic neck. The long-term outcomes of FEVAR are not well described and therefore the aim of this study was to perform an analysis of a national registry in the UK.
methodsThe UK GLOBALSTAR registry (2003-2022) was analysed to report the long-term outcomes of FEVAR. Patients were included if they underwent FEVAR with custom-made devices for infradiaphragmatic aortic aneurysmal disease. Patients with extent I-III thoracoabdominal aneurysms or those who underwent other complex EVAR techniques were excluded. Time-to-event analyses were conducted for survival, aneurysm-related mortality, reintervention, endoleak, and target vessel patency. Subgroup analyses were conducted for octogenarians and patient sex.
resultsSome 1651 patients across 15 centres were included. The median age was 75 (interquartile range 69-79) years and 87.9% were male. Estimated survival at 3, 5, and 10 years was 79.5% (95% c.i. 77.6% to 81.5%), 64.1% (95% c.i. 61.7% to 66.6%), and 30.5% (95% c.i. 27.7% to 33.5%) respectively; median survival was 6.9 (95% c.i. 6.6 to 7.2) years. Aneurysm-related mortality was 6.4% (95% c.i. 5.1% to 7.7%) at 10 years. There were 36 secondary sac ruptures over follow-up. The cumulative incidence of reintervention at 3, 5, and 7 years was 21.5% (95% c.i. 19.5% to 23.6%), 25.6% (95% c.i. 23.4% to 27.8%), and 27.6% (95% c.i. 25.3% to 30.0%) respectively. Graft-related complications accounted for 74.5% of reinterventions. Women had significantly worse 2-year survival (81.1% (95% c.i. 75.8% to 86.8%)) than men (86.1% (95% c.i. 84.3% to 87.9%)) (P = 0.041), driven by increased perioperative mortality. Beyond 2 years, the differences in survival were not statistically significant. Octogenarians had equivalent survival (89.4% (95% c.i. 86.4% to 92.4%)) to non-octogenarians (92.1% (95% c.i. 90.7% to 93.6%)) up to 1 year (P = 0.074). Octogenarians' median survival was 5.4 (95% c.i. 5.0 to 6.1) years.
conclusionsLong-term outcomes of FEVAR appear acceptable, with low rates of secondary sac rupture. FEVAR is associated with a significant risk of reintervention, with graft-related complications being a key driver, suggesting effective planning and graft surveillance are key to long-term durability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.